Charles River Laboratories Intl. (NYSE:CRL) issued an update on its FY18 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $5.87-5.97 for the period, compared to the Thomson Reuters consensus estimate of $5.91. The company issued revenue guidance of $2.25-2.27 billion, compared to the consensus revenue estimate of $2.23 billion.
CRL traded down $0.13 during trading on Thursday, reaching $136.10. 502,077 shares of the stock traded hands, compared to its average volume of 375,486. The company has a current ratio of 1.72, a quick ratio of 1.48 and a debt-to-equity ratio of 1.52. The stock has a market capitalization of $6.01 billion, a P/E ratio of 25.83, a price-to-earnings-growth ratio of 1.57 and a beta of 0.74. Charles River Laboratories Intl. has a 12 month low of $96.70 and a 12 month high of $138.89.
Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings results on Wednesday, November 7th. The medical research company reported $1.53 EPS for the quarter, beating the Zacks’ consensus estimate of $1.38 by $0.15. The business had revenue of $585.30 million for the quarter, compared to analysts’ expectations of $567.58 million. Charles River Laboratories Intl. had a net margin of 6.38% and a return on equity of 25.26%. The business’s quarterly revenue was up 26.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.30 earnings per share. As a group, research analysts predict that Charles River Laboratories Intl. will post 5.91 EPS for the current fiscal year.
In other news, insider David Ross Smith sold 1,249 shares of the stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $120.05, for a total transaction of $149,942.45. Following the transaction, the insider now owns 13,690 shares of the company’s stock, valued at approximately $1,643,484.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Deborah Turner Kochevar sold 4,066 shares of the stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $123.66, for a total transaction of $502,801.56. Following the transaction, the director now directly owns 10,190 shares in the company, valued at approximately $1,260,095.40. The disclosure for this sale can be found here. Insiders have sold a total of 28,671 shares of company stock worth $3,829,160 in the last three months. Insiders own 2.10% of the company’s stock.
About Charles River Laboratories Intl.
Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).
Further Reading: Hedge Funds Explained
Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.